<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119712</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00021565</org_study_id>
    <nct_id>NCT05119712</nct_id>
  </id_info>
  <brief_title>Terbinafine Treatment of Axial Spondyloarthropathy</brief_title>
  <acronym>FUN</acronym>
  <official_title>Terbinafine Treatment of Axial Spondyloarthropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Malassezia Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine if further research is warranted to assess if anti-fungal&#xD;
      therapy is an effective adjunctive treatment for axial spondyloarthropathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to determine if terbinafine is an effective therapy for&#xD;
      ankylosing spondylitis. Benefit will be determined by a reduction of the BASDAI by two or&#xD;
      more.&#xD;
&#xD;
      The primary endpoint is the BASDAI at the completion of 16 weeks of terbinafine versus the&#xD;
      BASDAI at the start of the trial and at the completion of the placebo. The secondary endpoint&#xD;
      with the percent of patients whose BASDAI improves by two or more while on terbinafine (week&#xD;
      16) versus the percent of subjects with a similar improvement after 16 weeks of placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will receive either terbinafine 500 mg or placebo for 16 weeks and then crossed over to the opposite therapy for another 16 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in BASDAI score</measure>
    <time_frame>16 weeks</time_frame>
    <description>BASDAI score after the completion of 16 weeks of terbinafine treatment versus the BASDAI score after 16 weeks on placebo. Benefit is defined by a reduction of BASDAI score of 2 or more.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Axial Spondyloarthritis</condition>
  <condition>Psoriatic Spondylitis</condition>
  <condition>Spondylitis Secondary to Inflammatory Bowel Disease</condition>
  <condition>Axial Spondyloarthopathy</condition>
  <arm_group>
    <arm_group_label>Placebo to Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will begin treatment on placebo then crossover to study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug to Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will begin treatment on study drug then crossover to placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine Tablets</intervention_name>
    <description>500mg oral terbinafine or placebo daily</description>
    <arm_group_label>Drug to Placebo</arm_group_label>
    <arm_group_label>Placebo to Drug</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory Testing</intervention_name>
    <description>Laboratory testing at screening, baseline, week 8, 16, 24 and 32.</description>
    <arm_group_label>Drug to Placebo</arm_group_label>
    <arm_group_label>Placebo to Drug</arm_group_label>
    <other_name>Blood work</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory Testing</intervention_name>
    <description>Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.</description>
    <arm_group_label>Drug to Placebo</arm_group_label>
    <arm_group_label>Placebo to Drug</arm_group_label>
    <other_name>Urinalysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects age 18 and older of either sex will be included.&#xD;
&#xD;
          -  Subjects must be willing and able to provide informed consent.&#xD;
&#xD;
          -  Subjects must have been diagnosed with ankylosing spondylitis, axial&#xD;
             spondyloarthritis, psoriatic spondylitis or spondylitis secondary to inflammatory&#xD;
             bowel disease by a physician and must be willing to request records to validate the&#xD;
             diagnosis.&#xD;
&#xD;
          -  Subjects must complete a symptom questionnaire called a BASDAI (Bath Ankylosing&#xD;
             Spondylitis Disease Activity Index) and must have a score of four or above to indicate&#xD;
             active disease and the potential to improve.&#xD;
&#xD;
          -  Subjects must agree to remain on a stable treatment regimen for their joint disease&#xD;
             for the duration of the trial and for one month before the study begins.&#xD;
&#xD;
          -  Subjects must be willing to provide stool samples and be willing to have routine lab&#xD;
             studies every 8 weeks during the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women will not be included.&#xD;
&#xD;
          -  Subjects must not be allergic or intolerant to terbinafine.&#xD;
&#xD;
          -  Subjects must not be taking medications that have the potential for serious&#xD;
             interactions with terbinafine. These drugs include desipramine, cimetidine,&#xD;
             fluconazole, cyclosporine and rifampin.&#xD;
&#xD;
          -  Subjects must not have taken antibiotics within 3 months of starting the study drug&#xD;
             and collecting the baseline stool specimen.&#xD;
&#xD;
          -  Subjects with the following blood dyscrasias will not be included:&#xD;
&#xD;
        Hemoglobin &lt;9g/dL or Hematocrit &lt;30% White blood cell count &lt;3.0 K/cu mm Absolute&#xD;
        neutrophil count &lt;1.2 K/cu mm Platelet count &lt;100 K/cu mm Subjects with an estimated GFR&#xD;
        â‰¤50 ml/min Subjects with a total bilirubin, AST, or ALT more than 1.5 times the upper limit&#xD;
        of normal at screening.&#xD;
&#xD;
          -  Severe, progressive, or uncontrolled chronic liver disease including fibrosis,&#xD;
             cirrhosis, or recent or active hepatitis.&#xD;
&#xD;
          -  History of any lymphoproliferative disorder such as Epstein Barr virus (EBV) related&#xD;
             lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms&#xD;
             suggest of current lymphatic disease.&#xD;
&#xD;
          -  Current malignancy or history of malignancy, with the exception of adequately treated&#xD;
             or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical&#xD;
             carcinoma in situ.&#xD;
&#xD;
          -  Have or have had an opportunistic infection (e.g., herpes zoster [shingles],&#xD;
             cytomegalovirus, Pneumocystis carinii, aspergillosis and aspergilloma, histoplasmosis,&#xD;
             or mycobacteria other than TB) within 6 months prior to screening.&#xD;
&#xD;
          -  Have a known infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Have current signs and symptoms of systemic lupus erythematosus, or severe,&#xD;
             progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary,&#xD;
             cardiac (New York Heart Association class III or IV), neurologic, or cerebral&#xD;
             diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James T Rosenbaum, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly M Ogle</last_name>
    <phone>(503) 494-5711</phone>
    <email>oglki@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Ogle</last_name>
      <phone>503-494-5711</phone>
      <email>oglki@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>James T Rosenbaum, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012 Jun;64(6):905-10. doi: 10.1002/acr.21621. Epub 2012 Jan 24.</citation>
    <PMID>22275150</PMID>
  </reference>
  <reference>
    <citation>Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol. 1985 Aug;24(3):242-9.</citation>
    <PMID>3160423</PMID>
  </reference>
  <reference>
    <citation>Asquith M, Rosenbaum JT. The interaction between host genetics and the microbiome in the pathogenesis of spondyloarthropathies. Curr Opin Rheumatol. 2016 Jul;28(4):405-12. doi: 10.1097/BOR.0000000000000299. Review.</citation>
    <PMID>27152700</PMID>
  </reference>
  <reference>
    <citation>Laurence M, Asquith M, Rosenbaum JT. Spondyloarthritis, Acute Anterior Uveitis, and Fungi: Updating the Catterall-King Hypothesis. Front Med (Lausanne). 2018 Apr 5;5:80. doi: 10.3389/fmed.2018.00080. eCollection 2018.</citation>
    <PMID>29675414</PMID>
  </reference>
  <reference>
    <citation>Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol. 1995 Dec;22(12):2266-72.</citation>
    <PMID>8835560</PMID>
  </reference>
  <reference>
    <citation>Maillet J, Ottaviani S, Tubach F, Roy C, Nicaise-Rolland P, Palazzo E, DieudÃ© P. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthritis: Prevalence and associated phenotype. Joint Bone Spine. 2016 Dec;83(6):665-668. doi: 10.1016/j.jbspin.2015.10.011. Epub 2016 Mar 15.</citation>
    <PMID>26992953</PMID>
  </reference>
  <reference>
    <citation>Gross O, Gewies A, Finger K, SchÃ¤fer M, Sparwasser T, Peschel C, FÃ¶rster I, Ruland J. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature. 2006 Aug 10;442(7103):651-6. Epub 2006 Jul 12.</citation>
    <PMID>16862125</PMID>
  </reference>
  <reference>
    <citation>Zhernakova A, Festen EM, Franke L, Trynka G, van Diemen CC, Monsuur AJ, Bevova M, Nijmeijer RM, van 't Slot R, Heijmans R, Boezen HM, van Heel DA, van Bodegraven AA, Stokkers PC, Wijmenga C, Crusius JB, Weersma RK. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet. 2008 May;82(5):1202-10. doi: 10.1016/j.ajhg.2008.03.016. Epub 2008 Apr 24.</citation>
    <PMID>18439550</PMID>
  </reference>
  <reference>
    <citation>Pointon JJ, Harvey D, Karaderi T, Appleton LH, Farrar C, Stone MA, Sturrock RD, Brown MA, Wordsworth BP. Elucidating the chromosome 9 association with AS; CARD9 is a candidate gene. Genes Immun. 2010 Sep;11(6):490-6. doi: 10.1038/gene.2010.17. Epub 2010 May 13. Erratum in: Genes Immun. 2011 Jun;12(4):319-20.</citation>
    <PMID>20463747</PMID>
  </reference>
  <reference>
    <citation>Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K, Velasco J, Strutton G, Tran A, Benham H, Rehaume L, Wilson RJ, Kikly K, Davies J, Pettit AR, Brown MA, McGuckin MA, Thomas R. Î²-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. Arthritis Rheum. 2012 Jul;64(7):2211-22. doi: 10.1002/art.34423.</citation>
    <PMID>22328069</PMID>
  </reference>
  <reference>
    <citation>Takahata Y, Sugita T, Hiruma M, Muto M. Quantitative analysis of Malassezia in the scale of patients with psoriasis using a real-time polymerase chain reaction assay. Br J Dermatol. 2007 Oct;157(4):670-3. Epub 2007 Jul 19.</citation>
    <PMID>17634085</PMID>
  </reference>
  <reference>
    <citation>Limon JJ, Tang J, Li D, Wolf AJ, Michelsen KS, Funari V, Gargus M, Nguyen C, Sharma P, Maymi VI, Iliev ID, Skalski JH, Brown J, Landers C, Borneman J, Braun J, Targan SR, McGovern DPB, Underhill DM. Malassezia Is Associated with Crohn's Disease and Exacerbates Colitis in Mouse Models. Cell Host Microbe. 2019 Mar 13;25(3):377-388.e6. doi: 10.1016/j.chom.2019.01.007. Epub 2019 Mar 5.</citation>
    <PMID>30850233</PMID>
  </reference>
  <reference>
    <citation>Babu PR, Pravin AJS, Deshmukh G, Dhoot D, Samant A, Kotak B. Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis. Indian J Dermatol. 2017 Jul-Aug;62(4):395-399. doi: 10.4103/ijd.IJD_191_17.</citation>
    <PMID>28794551</PMID>
  </reference>
  <reference>
    <citation>Chapman SW, Pappas P, Kauffmann C, Smith EB, Dietze R, Tiraboschi-Foss N, Restrepo A, Bustamante AB, Opper C, Emady-Azar S, Bakshi R. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004 Feb;47(1-2):62-8.</citation>
    <PMID>14998402</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jim Rosenbaum</investigator_full_name>
    <investigator_title>Professor of Ophthalmology, Medicine, and Cell Biology, OHSU</investigator_title>
  </responsible_party>
  <keyword>fungus, malassezia, microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Spondylarthropathies</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

